Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active…
WATCHLIST OCT 16 2026 Benzinga PreMarket Gainers (% change and volume) $EVTL $HODO $ZTG $NCPL $TCRT $KOLD $JAGX $SXTC $AIXI $RUBI $UAMY $IRD $AEHL Read our Benzinga Review here: https://t.co/DbZGLBN9ND https://t.co/iYsdtY1rOC
Consensus price target: $262.50 (+64875.25% upside from $0.40)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $11.51M | -1.52% | $-53.43M |
| 2024 | $11.69M | +19.75% | $-38.49M |
| 2023 | $9.76M | -18.36% | $-41.3M |
Stock data for JAGX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics